Publications by authors named "Michael Manyak"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

143,244

Total Likes

2,212

Extended Reach

147,560

Social Features

5
L
Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia.
Yuichiro Tsunemi, Ryokichi Irisawa, Hiromu Yoshiie, Betsy Brotherton, Hisahiro Ito, Ryoji Tsuboi, Makoto Kawashima, Michael Manyak,

J Dermatol· September 2016

Videos about Article: user user

2 1 2 2 10

View All Article and Social Media Activity
N
NRX-101 (D-Cycloserine + Lurasidone) Is Active against Drug-Resistant Urinary Pathogens In Vitro.
Michael T Sapko, Michael Manyak, Riccardo Panicucci, Jonathan C Javitt

Antibiotics (Basel)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding Treatment Response in Individual Profiles of Men with Prostatic Enlargement at Risk of Progression.
Stavros Gravas, Juan Manuel Palacios-Moreno, Douglas Thompson, Federico Concas, Piotr J Kamola, Michael Manyak

Eur Urol Focus· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a 3-item screening tool to identify men with benign prostatic enlargement/obstruction in a primary care cohort.
Andrea Tubaro, Mauro Niero, Burkay Adalig, Zrinka Lulic, Janet Plastino, Michael J Manyak

Minerva Urol Nephrol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-based meta-analysis of the time to first acute urinary retention or benign prostatic hyperplasia-related surgery in patients with moderate or severe symptoms.
Salvatore D'Agate, Chandrashekhar Chavan, Michael Manyak, Juan Manuel Palacios-Moreno, Matthias Oelke

Br J Clin Pharmacol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression.
Salvatore D'Agate, Chandrashekhar Chavan, Michael Manyak, Juan Manuel Palacios-Moreno, Matthias Oelke

World J Urol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-based meta-analysis of individual International Prostate Symptom Score trajectories in patients with benign prostatic hyperplasia with moderate or severe symptoms.
Salvatore D'Agate, Timothy Wilson, Burkay Adalig, Michael Manyak, Juan Manuel Palacios-Moreno

Br J Clin Pharmacol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Men's Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo-controlled study.
Claus G Roehrborn, Raymond C Rosen, Michael J Manyak, Juan Manuel Palacios-Moreno, Timothy H Wilson

Int J Clin Pract· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH.
Salvatore D'Agate, Timothy Wilson, Burkay Adalig, Michael Manyak, Juan Manuel Palacios-Moreno

World J Urol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): A post hoc analysis of a prospective randomised placebo-controlled study.
Raymond C Rosen, Claus G Roehrborn, Michael J Manyak, Juan Manuel Palacios-Moreno, Timothy H Wilson

Int J Clin Pract· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superiority of dutasteride 0.5 mg and tamsulosin 0.2 mg for the treatment of moderate-to-severe benign prostatic hyperplasia in Asian men.
Nazneen Haque, Naoya Masumori, Sadaaki Sakamoto, Zhangqun Ye, Sang-Jin Yoon, Michael Manyak

Int J Urol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter to the Editor: androgenetic alopecia; drug safety and therapeutic strategies.
Gary Ong, Michael Manyak, Zrinka Lulic

Expert Opin Drug Saf· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative Bioavailability of Fixed-Dose Combinations of Tamsulosin and Dutasteride: Results From 2 Randomized Trials in Healthy Male Volunteers.
Olivia Burns, John Zhu, Michael J Manyak, Ramiya Ravindranath, Fariba Koosha

Clin Pharmacol Drug Dev· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
Claus G Roehrborn, Michael J Manyak, Juan Manuel Palacios-Moreno, Timothy H Wilson, Erik P M Roos

BJU Int· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers.
Cindy Ke Zhou, Frank Z Stanczyk, Muhannad Hafi, Carmela C Veneroso, Barlow Lynch, Michael J Manyak

Prostate· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationships between Circulating and Intraprostatic Sex Steroid Hormone Concentrations.
Michael B Cook, Frank Z Stanczyk, Shannon N Wood, Ruth M Pfeiffer, Muhannad Hafi, Michael J Manyak

Cancer Epidemiol Biomarkers Prev· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioequivalence Studies of a Reformulated Dutasteride and Tamsulosin Hydrochloride Combination Capsule and a Commercially Available Formulation.
Renee Kurczewski, Chet Bowen, David Collins, John Zhu, Gulyeter Serbest, Michael Manyak

Clin Pharmacol Drug Dev· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding patient and physician perceptions of male androgenetic alopecia treatments in Asia-Pacific and Latin America.
Zrinka Lulic, Shigeki Inui, Woo-Young Sim, Hoon Kang, Gwang Seong Choi, Michael Manyak

J Dermatol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.
Claus G Roehrborn, Igor Oyarzabal Perez, Erik P M Roos, Nicolae Calomfirescu, Betsy Brotherton, Michael J Manyak

World J Urol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding patient and physician perceptions of benign prostatic hyperplasia in Asia Pacific, Latin America and the Commonwealth of Independent States: the Prostate Research on Behaviour and Education (PROBE) II survey.
Phillip Ertel, Burkay Adalig, Ipek Demircan, Belinda Lartey, Michael J Manyak

Int J Clin Pract· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Formulation on the Pharmacokinetics of Dutasteride: Results from Two Phase I Studies.
Michael Fossler, John Zhu, Claus Roehrborn, Paul McAleese, Michael Manyak

Clin Drug Investig· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.
Claus G Roehrborn, Igor Oyarzabal Perez, Erik P M Roos, Nicolae Calomfirescu, Betsy Brotherton, Michael J Manyak

BJU Int· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Franklin M Chu, Oliver Sartor, Leonard Gomella, Todd Rudo, Matthew C Somerville, Michael J Manyak

Eur J Cancer· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nocturia improvement in the combination of Avodart(®) and tamsulosin (CombAT) study.
Matthias Oelke, Claus G Roehrborn, Carlos D'Ancona, Timothy H Wilson, Ramiro Castro, Michael Manyak

World J Urol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a pooled analysis of three phase III studies.
Matthias Oelke, Claus G Roehrborn, Carlos D'Ancona, Timothy H Wilson, Ramiro Castro, Michael Manyak

World J Urol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis